#Celcuity
November 10, 2026 at 7:05 PM
November 9, 2026 at 3:55 PM
#CELC Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic…

https://www.stocktitan.net/news/CELC/celcuity-announces-fda-acceptance-of-s-nda-for-revtorpyktm-aqro7lxzfbcd.html?utm_source=stocktitan-bluesky&utm_medium=social
Celcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
Celcuity (Nasdaq: CELC) announced FDA acceptance of its supplemental application to expand REVTORPYK use to PIK3CA-mutant advanced breast cancer. The FDA set a June 25, 2027 target decision date. The proposed indication covers HR-positive, HER2-negative locally advanced or metastatic breast cancer with a PIK3CA mutation after progression on or after at least one line of endocrine therapy in the metastatic setting.The application draws on the PIK3CA-mutant cohort of the Phase 3 VIKTORIA-1 trial. REVTORPYK, or gedatolisib, received FDA approval on July 14, 2026, with fulvestrant, with or without palbociclib, for the corresponding population without a detected PIK3CA mutation. Celcuity said approval of the expansion would make REVTORPYK available as second-line therapy regardless of tumor PIK3CA status. The expanded indication remains under review.
www.stocktitan.net
November 9, 2026 at 1:30 PM
$8,435 traded in #$CELC options, split $7,970 calls / $465 puts (94% calls).
Off-exchange (dark pool) shares, % of volume: Nov 10 407,785 (53.0%).

Read the full article for the full details.
#optionsflow #stocks #optionstrading #stockmarket
Celcuity (CELC) Technical Levels: Options Flow Mixed Between $65.42 and $73.28
CELC at $65.92: support $65.42, resistance $73.28; the chart, options flow and dark pools are mixed.
globaltradersacademy.com
November 11, 2026 at 5:21 PM
Celcuity $CELC reported Q3 2026 Adj EPS of -$1.21, beating the -$1.52 estimate by 20.4%. Revenue of $0 missed the $881,280 estimate by 100.0%.

https://fundspec.ai/s/CELC/earnings
Screen valuation, momentum and options flow together in one place.
November 5, 2026 at 9:11 PM
🚨 $CELC
On November 05, 2026, Celcuity Inc. issued a press release regarding the Company’s financial results for the quarter ended September 30, 2026. A copy of the Company’s press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.
SEC Filing: CELC
Click to view the official SEC document.
www.sec.gov
November 5, 2026 at 9:08 PM
Celcuity #$CELC will hold three fireside chats in November.

CEO Brian Sullivan speaks on Nov 10, Nov 11 and Nov 18.

Shares closed at $67.07 Mon: below SMA50, below SMA200, RSI 45.

Hub: www.merlintrader.com/celc-celcuit...

Not investment advice.
CELC Stock: Celcuity News, REVTORPYK & Uptake
Celcuity stock news and analysis: the REVTORPYK launch, the submitted mutant indication, liquidity, convertible obligations and the key risks for CELC holders.
www.merlintrader.com
November 3, 2026 at 4:16 PM
$CELC Oct 23, 2026: At ESMO, Celcuity presented gedatolisib + darolutamide data in metastatic castration-resistant prostate cancer (45 pts): median rPFS 15.7 months (82.2% at 6 months) after prior abiraterone and 9.1 months after prior enzalutamide.

https://www.merlintrader.com/celc-celcuity-inc/
Celcuity $CELC: REVTORPYK Commercial Launch Confirmed
Celcuity confirms U.S. commercial availability of REVTORPYK on September 30. Uptake and revenue remain unreported; the mutant-cohort sNDA is separate.
www.merlintrader.com
October 23, 2026 at 4:28 PM
$CELC Latest analyst update, Oct 22, 2026: Cantor Fitzgerald started coverage of Celcuity at Overweight with a $140 target (third-party opinion), now that REVTORPYK is on the US market.

https://www.merlintrader.com/celc-celcuity-inc/
Celcuity $CELC: REVTORPYK Commercial Launch Confirmed
Celcuity confirms U.S. commercial availability of REVTORPYK on September 30. Uptake and revenue remain unreported; the mutant-cohort sNDA is separate.
www.merlintrader.com
October 22, 2026 at 8:13 PM
$CELC Latest analyst update, Oct 21, 2026: TD Cowen set a $145 price target on Celcuity. Third-party analyst opinion.

https://www.merlintrader.com/celc-celcuity-inc/
Celcuity $CELC: REVTORPYK Commercial Launch Confirmed
Celcuity confirms U.S. commercial availability of REVTORPYK on September 30. Uptake and revenue remain unreported; the mutant-cohort sNDA is separate.
www.merlintrader.com
October 21, 2026 at 10:43 PM
📅 CATALYST REMINDER | #$CELC
October 19, 23 & 24, 2026 — ESMO Abstracts & Clinical Data
Oct 19: ESMO abstracts (VIKTORIA-1 LBA16). Oct 23: Phase 1b gedatolisib prostate cancer data. Oct 24: VIKTORIA-1 subgroups.
🔗 Full details: www.merlintrader.com/celc-celcuit...
#CELC #Biotech #ESMO2026
Celcuity $CELC: REVTORPYK Commercial Launch Confirmed
Celcuity confirms U.S. commercial availability of REVTORPYK on September 30. Uptake and revenue remain unreported; the mutant-cohort sNDA is separate.
www.merlintrader.com
October 17, 2026 at 4:31 PM